Company Description
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.
It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Lara Sullivan |
Contact Details
Address: 321 Harrison Avenue, 11th Floor, Suite 1 Boston, Massachusetts 02118 United States | |
| Phone | 617 453 3596 |
| Website | pyxisoncology.com |
Stock Details
| Ticker Symbol | PYXS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782223 |
| CUSIP Number | 747324101 |
| ISIN Number | US7473241013 |
| Employer ID | 83-1160910 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lara S. Sullivan M.D., MBA | Chief Executive Officer, President, Chief Medical Officer and Director |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio and Program Management |
| Stephen T. Worsley MBA | Senior Vice President and Chief Business Officer |
| Dr. Michael Bui | Head of Global Regulatory Affairs |
| Dr. Supriya Roth Ph.D. | Head of Commercial Development |
| Dr. Shui He Ph.D. | Head of Biometrics |
| Dr. Hongwei Wang M.D., Ph.D. | Head of ADC Development and Clinical Strategy |
| Marsha Crochiere Ph.D. | Head of Translational Medicine and Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jul 3, 2025 | 8-K | Current Report |
| Jul 1, 2025 | SCHEDULE 13G | Filing |
| Jun 18, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 6, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | 144 | Filing |